431058-65-0
431058-65-0
Chemical Structure
DX-619
- CAS No.: 431058-65-0
- Formula:C21H24FN3O4
- Molecular Weight:401.43
InChIKey: ZLICIITZJTYKAQ-DIOULYMOSA-N
SMILES: COC1=C2N([C@H]3[C@H](C3)F)C=C(C(C2=CC=C1N4C[C@H](C5(CC5)N)CC4)=O)C(O)=O
Biological Activity: DX-619 is an antibacterial agent. DX-619 inhibits bacterial type II topoisomerases, DNA gyrase (GyrA), and topoisomerase IV (GrlA). DX-619 can be used in research related to bacterial infections, pneumonia, and other conditions[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DX-619 | DX-619 is an antibacterial agent. DX-619 inhibits bacterial type II topoisomerases, DNA gyrase (GyrA), and topoisomerase IV (GrlA). DX-619 can be used in research related to bacterial infections, pneumonia, and other conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Imamura Y, et al. Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. Pharmaceutical research. 2013 Feb;30(2):447-57.
- [2]. Fujikawa K, et al. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrobial agents and chemotherapy. 2005 Jul;49(7):3040-5. [Content Brief]
- [3]. Bogdanovich T, et al. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrobial agents and chemotherapy. 2005 Aug;49(8):3325-33. [Content Brief]
- [4]. Sarapa N, et al. Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol. Antimicrobial agents and chemotherapy. 2007 Jun;51(6):1912-7.
- [5]. Tanaka K, et al. In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone. Antimicrobial agents and chemotherapy. 2006 Nov;50(11):3908-13.
- [6]. Fukuda Y, et al. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrobial agents and chemotherapy. 2006 Jan;50(1):121-5.
